Abstract
Leukocyte interleukin-3 receptor α (CD123) is regarded as a marker of leukemia stem cells. We previously found that CD123 was also highly expressed on CD34+CD38– cells in myelodysplastic syndrome (MDS) patients, but it is unclear whether the level and the characteristics of CD34+CD38–CD123+ cells in MDS are similar to those in acute myeloid leukemia (AML). Based on previous research by our team, we further enlarged the specimens and found that the mean proportion and the mean MFI of CD34+CD38–CD123+ cells in low-grade MDS were lower than that in AML, and those in high-grade MDS were similar to those in AML. CD34+CD38–CD123+ cells expressed lower granulocyte stimulating factor receptor, CD11b, and apoptosis molecule (Annexin V), meanwhile, these cells showed upregulation of transcription factors (GATA-1, GATA-2) and transferrin receptor (CD71) in MDS and AML. Furthermore, an increase in CD34+CD38–CD123+ cells was closely related to the number of cytopenias involving hematopoietic lineages, anemia, blast count in bone marrow smear, fluorescence in situ hybridization analysis and WHO prognostic scoring system score. Thus, increases in CD34+CD38–CD123+ cells may reflect malignant clonal cells with aberrant differentiation, overproliferation, and decreased apoptosis in MDS, which were similar to AML. CD123 may thus be a promising indicator for identifying malignant clonal cells in MDS and a candidate for targeted therapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Testa U, Riccioni R, Militi S, Coccia E, Stellacci E, Samoggia P, et al. Elevated expression of IL-3Rα in acute myelogenous leukemia is associated with enhanced blast proliferation, increased cellularity, and poor prognosis. Blood. 2002;100:2980–8.
Yue L, Shao Z. Multi-parameter diagnosis of myelodysplastic syndrome. Chin J Pract Intern Med. 2010;30(5):389–92.
Yue LZ, Fu R, Wang HQ, Li LJ, Shao ZH. Expression of CD123 and CD114 on the bone marrow cells of patients with myelodysplastic syndrome. Chin Med J (Engl). 2010;123(15):2034–7.
Tang G, Jorgensen LJ, Zhou Y, Hu Y, Kersh M, Wang SA, et al. Multi-color CD34+ progenitor-focused flow cytometric assay in evaluation of myelodysplastic syndromes in patients with post cancer therapy cytopenia. Leuk Res. 2012;36(8):974–81.
De Smet D, Trullemans F, Jochmans K, Renmans W, Smet L, De Waele M, et al. Diagnostic potential of CD34+ cell antigen expression in myelodysplastic syndromes. Am J Clin Pathol. 2012;138(5):732–43.
Liu BN, Fu R, Wang HQ, Li LJ, Yue LZ, Shao ZH, et al. STAT5 phosphorylation in CD34 (+)CD38(−)CD123(+) bone marrow cells of the patients with myelodysplastic syndrome. Zhonghua Xue Ye Xue Za Zhi. 2012;33(6):480–3.
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937–51.
Hwang K, Park CJ, Jang S, Chi HS, Kim DY, Lee JH, et al. Flow cytometric quantification and immunophenotyping of leukemic stem cells in acute myeloid leukemia. Ann Hematol. 2012;91(10):1541–6.
De Smet D, Trullemans F, Jochmans K, Renmans W, Smet L, Heylen O, et al. Diagnostic potential of CD34+ cell antigen expression in myelodysplastic syndromes. Am J Clin Pathol. 2012;138(5):732–43.
Walter MJ, Shen D, Shao J, Ding L, White BS, et al. Clonal diversity of recurrently mutated genes in myelodysplastic syndromes. Leukemia. 2013;27(6):1275–82.
Shaffer LG, Ballif BC, Schultz RA. The use of cytogenetic microarrays in myelodysplastic syndrome characterization. Methods Mol Biol. 2013;973:69–85.
Miyazato A, Ueno S, Ohmine K, Ueda M, Yoshida K, Yamashita Y, et al. Identification of myelodysplastic syndrome-specific genes by DNA microarray analysis with purified hematopoietic stem cell fraction. Blood. 2001;98:422–7.
Spinelli E, Caporale R, Buchi F, Masala E, Gozzini A, Sanna A, et al. Distinct signal transduction abnormalities and erythropoietin response in bone marrow hematopoietic cell subpopulations of myelodysplastic syndrome patients. Clin Cancer Res. 2012;18(11):3079–89.
Graf M, Hecht K, Reif S, Pelka-Fleischer R, Pfister K, Schmetzer H. Expression and prognostic value of hemopoietic cytokine receptors in acute myeloid leukemia (AML): implications for future therapeutical strategies. Eur J Haematol. 2004;72:89–106.
Santini V. Treatment of low-risk myelodysplastic syndrome: hematopoietic growth factors erythropoietins and thrombopoietins. Semin Hematol. 2012;49(4):295–303.
Newman K, Maness-Harris L, El-Hemaidi I, Akhtari M. Revisiting use of growth factors in myelodysplastic syndromes. Asian Pac J Cancer Prev. 2012;13(4):1081–91.
Park S, Grabar S, Kelaidi C, Beyne-Rauzy O, Picard F, Bardet V, et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood. 2008;111(2):574–82.
Beekman R, Touw IP. G-CSF and its receptor in myeloid malignancy. Blood. 2010;115(25):5131–6.
Kimura A, Sultana TA. Granulocyte colony-stimulating factor receptors on CD34+ cells in patients with myelodysplastic syndrome (MDS) and MDS-acute myeloid leukemia. Leuk Lymphoma. 2004;45:1995–2000.
Testa U, Riccioni R, Biffoni M, Diverio D, Lo-Coco F, Foà R, et al. Diphtheria toxin fused to variant human interleukin-3 induces cytotoxicity of blasts from patients with acute myeloid leukemia according to the level of interleukin-3 receptor expression. Blood. 2005;106(7):2527–9.
Cantor AB, Iwasaki H, Arinobu Y, Moran TB, Shigematsu H, Sullivan MR, et al. Antagonism of FOG-1 and GATA factors in fate choice for the mast cell lineage. J Exp Med. 2008;205:611–24.
Arinobu Y, Mizuno S, Chong Y, Shigematsu H, Iino T, Iwasaki H, et al. Reciprocal activation of GATA-1 and PU.1 marks initial specification of hematopoietic stem cells into myelo erythroid and myelo lymphoid lineages. Cell Stem Cell. 2007;12:416–27.
Ayala RM, Martínez-López J, Albízua E, Diez A, Gilsanz F. Clinical significance of Gata-1, Gata-2, EKLF, and c-MPL expression in acute myeloid leukemia. Am J Hematol. 2009;84:79–86.
Dong HY, Wilkes S, Yang H. CD71 is selectively and ubiquitously expressed at high levels in erythroid precursors of all maturation stages: a comparative immunochemical study with glycophorin A and hemoglobin A. Am J Surg Pathol. 2011;35(5):723–32.
Callens C, Coulon S, Naudin J, Radford-Weiss I, Boissel N, Raffoux E, et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. J Exp Med. 2010;207(4):731–50.
Janssen JJ, Deenik W, Smolders KG, van Kuijk BJ, Pouwels W, et al. Residual normal stem cells can be detected in newly diagnosed chronic myeloid leukemia patients by a new flow cytometric approach and predict for optimal response to imatinib. Leukemia. 2012;26(5):977–84.
Yalcintepe L, Frankel AE, Hogge DE. Expression of interleukin-3 receptor subunits on defined subpopulations of acute myeloid leukemia blasts predicts the cytotoxicity of diphtheria toxin interleukin-3 fusion protein against malignant progenitors that engraft in immunodeficient mice. Blood. 2006;108(10):3530–7.
Stein C, Kellner C, Kügler M, Reiff N, Mentz K, Schwenkert M, et al. Novel conjugates of single-chain Fv antibody fragments specific for stem cell antigen CD123 mediate potent death of acute myeloid leukaemia cells. Br J Haematol. 2010;148(6):879–89.
Conflict of interest
The authors declare that there is no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Additional information
L. J. Li and J. L. Tao contributed equally to this work.
About this article
Cite this article
Li, L.J., Tao, J.L., Fu, R. et al. Increased CD34+CD38−CD123+ cells in myelodysplastic syndrome displaying malignant features similar to those in AML. Int J Hematol 100, 60–69 (2014). https://doi.org/10.1007/s12185-014-1590-2
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-014-1590-2